Table 1.
Baseline clinical and demographic characteristics of all participants included in the analysis, and characteristics by treatment group. ART: Antiretroviral Therapy; DTG: Dolutegravir; NNRTI: Non-nucleoside reverse-transcriptase inhibitor. BMI: Body mass index (body mass in kg divided by square of body height in m2).
| All ART regimens | NNRTI-based regimens | DTG-based regimens | p-value | ||
|---|---|---|---|---|---|
| Total, N (%) | 17,044 | 16,517 (97%) | 527 (3%) | NA | |
| Year ART Start | 2016 | 7295 (43%) | 7295 (44%) | 0 (0%) | <0.001 |
| 2017 | 5654 (33%) | 5630 (34%) | 24 (5%) | ||
| 2018 | 4095 (24%) | 3592 (22%) | 503 (95%) | ||
| Age in years, median (IQR) | 36.8 (30.0, 45.2) | 36.8 (29.9, 45.1) | 38.7 (31.6, 47.0) | <0.001 | |
| Sex at birth, N (%) | Female | 10,518 (62%) | 10,268 (62%) | 250 (47%) | <0.001 |
| Male | 6,526 (38%) | 6,249 (38%) | 277 (53%) | ||
| Participants with available baseline BMI, N (%) | 15,555 (91%) | 15,080 (91%) | 475 (90%) | 0.35 | |
| Baseline weight (kg), median (IQR) | 58.0 (51.0, 65.0) | 58.0 (51.0, 65.0) | 59.0 (50.5, 65.0) | 0.81 | |
| Baseline BMI (kg/m 2 ), median (IQR) | 20.8 (18.7, 23.5) | 20.8 (18.7, 23.5) | 20.4 (18.2, 23.1) | 0.01 | |
| Baseline BMI Category, N (%) | Underweight (BMI < 18.5) | 3,570 (21%) | 3,436 (21%) | 134 (25%) | 0.02 * |
| Normal (18.5 ≤ BMI < 25) | 9,232 (54%) | 8,960 (54%) | 272 (52%) | ||
| Overweight (25 ≤ BMI < 30) | 2,027 (12%) | 1,972 (12%) | 55 (10%) | ||
| Obese (BMI ≥ 30) | 726 (4%) | 712 (4%) | 14 (3%) | ||
| Missing | 1,489 (9%) | 1,437 (9%) | 52 (10%) | ||
| Participants with available baseline CD4 count, N (%) | 5,401 (35%) | 5,240 (35%) | 161 (34%) | 0.57 | |
| Baseline CD4 count (cells/mm 3 ), median (IQR) | 298.0 (125.0, 493.0) | 299.0 (125.0, 493.0) | 262.0 (130.0, 506.0) | 0.88 | |
| Baseline CD4 count range (in cells/mm 3 ), N (%) | < 200, N (%) | 1974 (11.6) | 1916 (11.6) | 58 (11.0) | 0.40 * |
| 200 – 350, N (%) | 1121 (6.6) | 1081 (6.5) | 40 (7.6) | ||
| >350, N (%) | 2306 (13.5) | 2243 (13.6) | 63 (12.0) | ||
| Missing | 11643 (68.3) | 11277 (68.3) | 366 (69.4) | ||
| Active Tuberculosis Therapy, N (%) | 1,056 (6%) | 1,016 (6%) | 40 (8%) | 0.18 | |
| Number of Viral Loads Measured, median (IQR) | 3.0(2.0,4.0) | 3.0(2.0,4.0) | 2.0(1.0,2.0) | <0.001 | |
| Length of Follow-Up (months), median (IQR) | 14.0(3.0,26.0) | 14.0(3.0,26.0) | 15.0(7.0,18.0) | <0.001 | |
*
missing not included in statistical comparison